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Human immunodeficiency virus type 1 (HIV-1) rapidly develops resistance to lamivudine during mono-
therapy, typically resulting in the appearance at position 184 in reverse transcriptase (RT) of isoleucine instead
of the wild-type methionine (M184I) early in therapy, which is later replaced by valine (M184V). M184V
reduces viral susceptibility to drug in vitro by approximately 100-fold, but also results in a lower processivity
of RT. We show that a drop in absolute viral fitness associated with the outgrowth of M184V results in a drop
in viral load only in individuals with high CD41 counts, from whom we estimate the relative fitness of M184V
in the presence of drug to be approximately 10% of that of the wild type prior to therapy. The timing of
emergence of the M184V mutant varies widely between infected individuals. From analysis of the frequency of
M184I and M184V mutants determined at multiple time points in seven individuals during lamivudine
therapy, we estimated the fitness advantage of M184V over M184I during therapy to be approximately 23% on
average. We have also estimated the average ratio of the frequencies of the two mutants prior to therapy to be
0.2:1, with a range from 0.12:1 to 0.33:1. We have found that the differences between individuals in the rate of
evolution of lamivudine resistance arise due to genetic drift affecting the relative frequency of M184I and
M184V prior to therapy. These results show that stochastic effects can be significant in HIV evolution, even
when there is large fitness difference between mutant and wild-type variants.
Resistance to the reverse transcriptase (RT) inhibitor lami-
vudine (3TC) involves mutations at one residue in RT, methi-
onine (ATG) position 184 (3, 29). Typically, after about 2
weeks of 3TC monotherapy, isoleucine (ATA) appears at this
position. Although this substitution confers a several-hundred-
fold increase in the 50% inhibitory concentration relative to
the wild type, it also dramatically reduces the replication rate
of the virus by reducing the processivity of the enzyme (1).
After 8 to 20 weeks, isoleucine is replaced by valine (GTG),
which also confers drug resistance but has less of an impact on
the processivity of RT, such that in the absence of drug, the
valine mutant has a fitness intermediate to that of wild type
and the isoleucine mutant in vitro.
The pattern of evolution of drug resistance to 3TC, with the
initial appearance of the M184I mutant, followed by the re-
placement of the fitter M184V mutant, has been explained in
terms of a balance between mutation and selection (26). In
human immunodeficiency virus (HIV), G-to-A mutations are
more common than A-to-G mutations and result in a higher
production rate of M184I mutants (13, 17). Based on the clas-
sical population genetics result that the frequency of a delete-
rious mutation reflects a balance between mutation and selec-
tion (9), this mutational bias towards A must be large enough
to overcome the higher fitness of M184V in order to result in
M184I mutants being present at higher frequencies than
M184V prior to therapy. This is consistent with in vitro studies
which have shown the mutation rate from wild type to M184I
is over four times higher than that to M184V (17), while the
enzymatic efficiency of M184V (45% relative to the wild type
for virion-derived RT) is less than twice that of M184I (28%)
(1). The replicative advantage of M184V over M184I during
therapy results in the eventual outgrowth of M184V despite its
lower initial frequency. However, the timing of the appearance
of the M184V mutant varies widely between individuals (26).
This could be due to different levels of resistance prior to
therapy or different rates of increase during therapy. Once
fixed, average viral loads associated with the M184V mutant
are lower than those associated with the wild type prior to
therapy. However, there is considerable variation in the viral
load response between individuals: some individuals show a
very marked reduction, while others even show an increase in
viral load.
It has been argued that the evolution of resistance is com-
pletely deterministic (5) because the number of productively
infected cells within the body is very high (4). Under this
assumption, between-host differences in the relative frequen-
cies of M184V to M184I prior to therapy reflect differences in
the relative fitnesses of these mutants, because the mutation
rate is unlikely to vary between individuals. In contrast, it has
been argued that chance effects may play an important role in
generating variation in the rate of evolution of drug resistance
(19, 20). These effects have been discussed by using the con-
cept of effective population size. Although the number of in-
fected cells may be very large, HIV may evolve as if it were a
smaller population. A high variance in the number of second-
ary infected cells produced per infected cell could increase the
importance of chance effects—an effect captured in the con-
cept of a “variance effective population size” (6, 31). A high
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variance may arise due to spatial differences in the level of
immune activation and spatial clustering of infected cells, such
that relatively few cells have access to target cells. Additionally,
selection acting in different directions on linked regions of the
HIV genome can give rise to “genetic conflicts” (8), which
could also lead to an apparently low effective population size
and increase the amount of noise in the evolution of drug
resistance.
In order to assess the relative importance of chance in the
evolution of 3TC resistance, we analyzed the dynamics of
M184V and M184I mutants in seven individuals on 3TC mono-
therapy in order to estimate the rate of outgrowth of M184V
over M184I and their relative frequency prior to therapy. We
have also analyzed the response of viral load to the outgrowth
of 184V in order to estimate the fitness of M184V during
therapy relative to that of the wild type prior to therapy. In
individuals with a low CD41 count, the decrease in viral fitness
associated with 184V has no effect on the viral load.
MATERIALS AND METHODS
Study population. The original study population consisted of 20 men with
asymptomatic or mildly symptomatic HIV-1 infection who were selected from a
cohort of 40 men treated with different doses (0.5 to 20.0 mg/kg of body weight/
day) of 3TC (Glaxo) monotherapy as part of a phase I to phase II trial (28).
Nineteen of these patients had an initial decline in HIV-1 RNA load. The
relative amounts of the wild type (methionine [ATG]) and resistant mutants
(isoleucine [ATA] or valine [GTG]) at position 184 in RT were determined by a
primer-guided nucleotide incorporation assay (14, 27).
To estimate the rate of viral decay, we analyzed those individuals who had at
least two viral load measurements taken during the first week of therapy, giving
a sample size of 16. In order to obtain accurate estimates of the relative fitness
of the M184I and the M184V mutants, we analyzed patients for which the
frequency of each resistant mutant was greater than 5% (the apparent limit of
detection) (26) and the total frequency was less than 100% for at least two time
points between 2 and 4 weeks of 3TC therapy. For these patients, time points
where the frequency of either mutant was less than 5% or was obscured by high
background levels were treated as random missing data. This reduced the sample
size to seven patients. To obtain estimates of relative fitness of M184V and the
wild type from the steady-state viral loads prior to and late during therapy, we
analyzed 16 patients who had initial viral loads associated with ,5% M184V and
final viral loads associated with .95% M184V. Fourteen of these patients also
had viral load data taken 1 to 2 weeks prior to therapy.
Estimation of the rate of viral decay during initial therapy. To estimate the
rate of viral decay, we fitted two linear models to the log viral load data, which
allowed the initial viral load to vary by patient. The first model assumed that the
rate of decay was the same in all patients, whereas the second allowed the rate
of decay to vary between individuals. These two models were compared by using
analysis of variance (ANOVA) and restricted maximum likelihood (REML).
Estimation of the relative fitness of M184V and M184I in vivo by using the
relative rates of outgrowth. In order to obtain estimates of the relative fitness of
the M184V and M184I drug-resistant mutants in vivo during therapy from the
observed frequency of resistant mutants, we employed a simple mathematical
model. The relative frequency of two mutants, p1 and p2, with constant fitnesses
of 1 1 s1 and 1 1 s2, respectively (s2 . s1, and the fitness of the wild type is 1)
over time in an infinite, well-mixed population can be calculated from standard
population genetics theory (equation 5.2.1 in reference 6). If time is given in
generations, the relative frequency over time is given by the expression
ln@p2~t!/p1~t!# 5 ln@p2~0!/p1~0!# 1 ~s2 2 s1!t (1)
Hence, if ln(p2/p1) is plotted against time, the intercept gives an estimate of the
relative frequency of the mutants prior to therapy and the slope gives an estimate
of the relative fitness of the mutants, which can be obtained by fitting linear
models. We assumed a generation time of 2.6 days (24).
We first estimated the relative fitness of M184V relative to M184I by averaging
across all seven patients, allowing the initial frequency of M184V relative to
M184I to vary between hosts by fitting a general linear model assuming an
identity link and independent normally distributed errors. We compared this to
a similar model in which both the initial frequency and the fitness of M184V were
the same between all individuals, by using the generalized estimating equation
approach (21). This allowed us to estimate the correlation between measure-
ments taken for the same individual and hence also allows us to test whether the
differences in the outgrowth of M184V are simply due to measurement error,
which results in uncorrelated residuals. We assumed normally distributed errors,
an identity link function, and a first-order autoregressive working correlation
structure for the residuals. The significance of the correlation between residuals
was calculated by randomizing measurements at each time point.
We also obtained estimates of the fitness of 184V, assuming that both the
initial frequency, ln[p2(0)/p1(0)], and the relative fitness, s2 2 s1, varied between
individuals. A similar approach has been used by Havlir et al. (10) and Eastman
et al. (7). Differences between hosts in the rate of increase of M184V during
therapy may arise due to differences in dose or in viral genetic background. Due
to the large number of extra parameters (seven patients, and so an additional six
parameters) in this model, we could not statistically test the improvement in fit.
Instead, we assumed that differences in the slope between individuals could be
approximated by a normal distribution with a mean of 0 and a variance of s2.
This allowed us to test whether there was significant variation in the slope
between individuals by only introducing one extra parameter. This was per-
formed by fitting a linear mixed-effects model by using REML.
Estimation of the relative fitness of M184V (in the presence of drug) to wild
type (in the absence of drug) by using the steady-state viral loads. The lower
viral load relative to the baseline associated with M184V suggested that the
relative fitness of M184V might be estimated from the ratio of final viral load to
initial viral load, which we call f. In order to test whether variation in f between
patients was due to factors such as initial viral load, dose, or CD41 count, we
fitted general linear models to the data. To test for homogeneity of variance, we
used restricted maximum likelihood and a power-law variance weighting func-
tion.
Statistical software. All statistical tests were performed in the R programming
language (http://www.ci.tuwien.ac.at/R/) by using the gee, boot, and lme libraries.
RESULTS
Estimates of the frequency of M184I and M184V mutants.
In all patients studied, the percentage of resistant mutants
increased over the duration of therapy, with a shift from M184I
to M184V (Fig. 1). However, there was considerable variation
among the seven individuals studied in terms of the rate of
evolution of resistance. For example, after 2 weeks of therapy,
in patient 22, the frequencies of M184I and M184V were 70
and 8%, respectively, while in patient 17, the frequencies were
31% for M184I and 66% for M184V. At the initiation of
therapy, six out of the seven patients had undetectable levels
(0%) of both mutants. In patient 17, before therapy, M184I
was at a frequency of 3% and M184V was at a frequency of
1%, although these low estimates are liable to considerable
measurement error.
Estimating the rate of viral decay. In order to determine
whether there were differences in drug efficacy between indi-
viduals, we estimated the rate of decay of plasma virus during
the first week of therapy by fitting a single slope to the log viral
load data for all individuals as suggested by previous studies.
This model was a very good fit to the data (ANOVA, 85.8% of
variation explained) and gave a decay rate of 20.31 (0.03
standard error [SE]), which equates to a half-life of 2.2 days,
similar to the rates of decay seen in nevirapine and ritonavir
FIG. 1. Estimates of the percentage of methionine (M [white]), isoleucine
(I [gray]), and valine (V [black]) at position 184 of RT after approximately 2, 3,
and 4 weeks of 3TC monotherapy.
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monotherapy (12, 24, 30). Similar estimates of decay rate were
obtained by using restricted maximum likelihood, allowing for
random variation in initial log viral load.
A model which allowed for variation in the viral decay rate
between individuals did not give a significantly better fit (ac-
cumulated ANOVA, F15,10 5 1.02, P 5 0.5; REML, deviance
[1 df] 5 0.15, P 5 0.7). We concluded that there was no
difference between individuals in the effect of drug on the
replication rate of wild-type virus.
Estimating fitness of resistant virus. It was not possible
directly to estimate the relative fitness of M184V to the wild
type with the small number of data points available for each
patient. However, we could estimate the relative fitness of the
two resistant strains of virus to each other from their relative
proportions over time, because the rate of replacement of
M184I by M184V was slow enough to be estimated with sam-
ples taken a week apart. When the log of the ratio of frequency
of M184V relative to M184I, ln(p2/p1), was plotted against
time, we observed substantial differences in frequency between
patients at any given time point, although the rate of increase
in 184V was relatively consistent between individuals (Fig. 2).
From this, we inferred that the starting frequencies of M184V
relative to M184I may differ among patients, but the fitness of
M184V was relatively constant between individuals. A linear
model with uniform slope but allowing for different intercepts
was therefore fitted to the data from all seven patients. The
estimated mean fitness difference was 22.57% (3.66% SE), and
the estimates of the ratio of initial frequencies ranged from
0.12:1 to 0.33:1 (mean, 0.20:1; coefficient of variation [CV],
0.43). This model fitted the data well, accounting for 77.9% of
the observed variation.
To test whether it was necessary to allow the initial fre-
quency of M184V relative to M184I to vary between hosts, we
also obtained parameter estimates assuming that both fitness
and prior frequency of M184V were the same between hosts.
This model gave a slightly lower estimate of the fitness advan-
tage of M184V (14.99%, 5.73% SE), and a higher average
prior frequency (0.37:1), but it gave a much poorer fit to the
data, accounting for only 28% of the observed variation, sig-
nificantly less than the model which allowed initial frequency
to vary between hosts (accumulated ANOVA, P 5 0.011).
The comparison of these models is hampered by the small
sample size (seven individuals) and measurement error. If the
apparent differences in the initial frequency arose due to high
measurement error, then the deviations from the average in-
crease should not be correlated over time; however, if there
were real underlying differences in the initial frequency, we
would expect to see a significant positive correlation (i.e., pa-
tients that have higher-than-average frequencies of M184V
early in therapy also have higher-than-average frequencies of
M184V late into therapy. We found a strong positive correla-
tion between measurements taken a week apart (r 5 0.696). To
test the significance of the observed correlation, we estimated
the correlation coefficient for 1,000 data sets where measure-
ments were randomized within time points. The observed cor-
relation was significantly higher than those calculated from the
randomized data set (mean 5 20.19, P 5 0.001). This argues
strongly that the deviations in initial frequency are not due to
measurement error.
Estimates of fitness and initial frequency treating patients
separately. We also fitted the linear model to the data from
each patient separately. Estimates of relative fitness and initial
frequency obtained in this way varied widely between patients
(Table 1). Estimates of fitness ranged from 7.2% (patient 15)
to 34.5% (patient 22), with an average across individuals of
23.3%. The relative frequency prior to therapy again varied
widely between individuals, from 0.042:1 in patient 22 to 0.85:1
in patient 17. Although this model accounted for a large
amount of the variation (96.9%), this was not a significantly
better fit than assuming no variation in fitness (accumulated
ANOVA, P 5 0.103). A similar analysis using restricted max-
imum likelihood, but where variation in the fitness of M184V
was assumed to be distributed normally between individuals,
gave a P value close to significance (P 5 0.06).
The evidence of variation in fitness from the maximum-
likelihood analysis of the full model, where both prior fre-
quency and relative fitness were assumed to vary between in-
dividuals, was equivocal. Hence, we also analyzed the variation
in the estimates of prior frequency and fitness for the full
model to determine whether they were biologically reasonable.
Surprisingly, a highly significant negative correlation was found
between the estimates of initial frequency and fitness (Spear-
man’s rank correlation 5 20.93; exact two-sided test, P 5
0.007). Under the assumption that differences in the initial
frequency and rates of increase would be due to differences in
viral genetic background, this makes little sense, because it
suggests that the rarer (i.e., less fit) a mutant is prior to ther-
apy, the fitter it is during therapy. This is unlikely for two
reasons. First, this hypothesis implies significant genetic vari-
ation with respect to 3TC resistance in HIV-1 RT among
different infected individuals, although no site with a large
effect other than 184 has consistently emerged during mono-
therapy. Second, given that the M184V mutant is fitter than
FIG. 2. Plot of the log ratio of the frequency of the valine to the isoleucine
mutants, ln(M184V/M184I), over time in generations, assuming a generation
time of 2.6 days for each patient.
TABLE 1. Estimates of the relative fitness and frequency of
M184V relative to M184I on a patient-by-patient basis
Patient identification
no.
Relative fitness advantage
of M184V over M184I
(s2 2 s1)
Initial
M184V/M184I ratio
11 0.276 0.079
15 0.072 0.681
17 0.082 0.846
21 0.302 0.197
22 0.345 0.042
26 0.345 0.045
34 0.208 0.350
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M184I even in the absence of drug (1), it is extremely unlikely
that the greater the fitness difference between M184V and
M184I, the rarer M184V is prior to therapy. In contrast, such
a negative correlation could easily arise as a statistical artifact,
because estimates of the slope and intercept of a straight line
are strongly negatively correlated. We conclude that there are
large differences in the ratio of initial frequencies, but the
evidence that these are related to fitness is weak.
A simple stochastic model of the relative frequency of
M184V and M184I prior to therapy. One explanation for the
variation in prior frequency is that the frequencies of M184V
and M184I fluctuate due to random genetic drift. To explore
this possibility, we developed a simple stochastic model which
describes the relative frequency of M184V to M184I prior to
therapy under different assumptions of the variance effective
population size, Ne (6, 31). Although at steady state, each
productively infected cell gives rise, on average, to one daugh-
ter productively infected cell, there is likely to be a very high
variance in the number of such daughter infected cells. Many
mechanisms can contribute to this, including poor mixing of
infected cells within the body and variation in the levels of
immune stimulation, such that some cells will have contact with
more uninfected target cells than others. The higher the vari-
ance, the more important genetic drift will be.
We assume that, for each patient, Ne is constant and the
mutation rates are m1 and m2 per replication cycle for the
production of M184I and M184V mutants, respectively, from
the wild type, with negligible mutation between them or back
to the wild type. We also assume the M184I and M184V
mutants carry a cost of resistance pretherapy of s1pre and s2pre,
respectively. From the theory of univariate birth-death pro-
cesses (16), it follows that the distribution of the number of
cells infected with a single resistant mutant in a group of
individuals follows a negative binomial distribution with mean
mNe/spre, variance mNe/spre
2, and index mNe/(1 2spre). Hence
the relative frequency of M184V to M184I prior to therapy in
an individual is the ratio of two random negative binomial
variables. The mean, E[p2/p1], and variance, Var[p2/p1], of the
ratio of M184V to M184I in a group of individuals can be
approximated by the delta method (18) to give
E Fp2~0!p1~0!G < m2s1 prem1s2 pre S1 1 1Nem1D (2)
Var Fp2~0!p1~0!G < Sm2s1 prem1s2 preD
2 S 1Nem1 1 1Nem2D (3)
The CV, CV[p2(0)/p1(0)], is approximately
CV Fp2~0!p1~0!G < Nem1Nem1 1 1 ˛m1 1 m2Nem1m2 (4)
Under this model, significant levels of variation prior to
therapy could occur solely by genetic drift. From equation 4, it
can be seen that the CV is independent of the cost of resis-
tance, only depending on the relative mutation rates from
wild-type virus and the effective population size. For reason-
able estimates of the relative mutation rates (fourfold) (17)
and costs of resistance in the absence of therapy (based on the
relative enzymatic efficiency of RT) (1), significant variation in
the relative frequencies of M184V to M184I can be obtained
for an effective population size as high as 106 (Fig. 3). Recent
estimates of Ne for HIV have been substantially lower than this
(19, 23), which would magnify the effect.
Our approach assumes that the rate of increase in M184V
over the period of study is deterministic, which is a reasonable
approximation given a fitness advantage for M184V over
M184I of around 20%, because chance effects have little im-
pact on mutations with such a large fitness advantage. There
are two ways in which the rise of M184V during the period of
study could deviate from a simple logistic increase. First, the
variance effective population size might be very low. In order
for this to be an important effect, the product of effective
population size and the selective advantage of M184V, Ne(s2 2
s1), must be small (,1). Even assuming a smaller fitness ad-
vantage of 10%, Ne would have to be extremely small (;10) to
result in significant deviations from a deterministic rise. Sec-
ondly, the fitness of an M184V mutant may be affected by
selection on genetic variation linked to position 184, resulting
in an apparently stochastic increase in frequency rather than a
smooth logistic increase in M184V. For this to be an important
effect, the probability that a mutant with a selective advantage
of more than 20% over M184I (i.e., s2 2 s1) emerges over the
2-week study period would have to be unrealistically high to
generate such variation between hosts.
Our simple stochastic model, together with consideration of
the size of the fitness difference in the 3TC-resistant mutants,
suggested that estimates of fitness and frequency based on our
hypothesis that there is a combination of genetic drift prior to
therapy, with an approximately deterministic increase during
therapy, are biologically plausible. We conclude that this
model is likely to be a good fit to the increase of M184V
relative to M184I over the period of study. However, these
mutants may be subject to genetic drift during the early stages
of therapy. Because the rarer mutant (M184V) is more subject
to genetic drift, it will take longer to enter a phase of deter-
ministic increase, and, hence, we are likely to underestimate
the relative frequency of M184V prior to therapy, even if the
absolute fitness of virus remains constant during therapy.
Estimation of the relative fitness of M184V compared to
that of the wild type. Although we could not estimate the
relative fitness of resistant virus compared to that of the wild
type by using the rate of viral outgrowth during early therapy,
the lower viral load associated with M184V at the equilibrium
reached during drug therapy suggested that its fitness relative
to that of the wild type might be estimated from the difference
FIG. 3. Approximate values for the mean and the CV of the frequency of
M184V relative to M184I prior to therapy, p2(0)/p1(0), for effective population
sizes between 105 and 108. The parameter values assumed were m1 5 6 3 1025,
m2 5 1.5 3 1025, s1 5 0.45, and s2 5 0.28. Similar results were obtained with a
wide range of parameter values.
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in equilibrium viral load between baseline and late therapy.
We used the ratio of final viral load to baseline viral load,
which we called f, as a measure of the change in viral load
associated with the outgrowth of M184V. Data on the viral
load in the period prior to therapy allow us to determine
whether variation in viral load response is different from
“background” variation.
On average, the viral load associated with M184V was 64.3%
that at baseline, although there was significant variation be-
tween individuals, with some individuals showing a marked
decrease and others even showing an increase (range of f 5 7.3
to 191%). We analyzed this variation by fitting a linear model.
Neither dose nor log initial viral load accounted for significant
variation in the decrease in viral load (dose: F1,14 5 0.18, P 5
0.68; viral load, F1,14 5 0.02, P 5 0.90, respectively). However,
we found a significant negative correlation between the de-
crease in viral load and CD41 count, with CD41 count ex-
plaining 28.1% of the variation (F1,14 5 6.85, P 5 0.02). When
the regression was plotted, it appeared that variation in the
reduction in viral load was higher for lower CD41 counts (Fig.
4), which was statistically significant (REML, power law
weighting function, exponent 5 1.2; P 5 0.04).
To investigate the interaction between the reduction in viral
load and CD41 count, we split individuals into two groups:
those that had CD41 counts of ,200 (n 5 8) and those that
had CD41 counts of 200 or more (n 5 8). Seven individuals in
each group also had viral load measurements taken 1 or 2
weeks prior to the initiation of therapy. This allowed us to
compare the variation in the reduction in viral load seen during
therapy with that prior to therapy (Fig. 5).
For individuals with a low CD41 count, the drop in viral
fitness due to the outgrowth of M184V appeared to have no
effect on the viral load, with no significant differences in the
mean (two-tailed paired t test, P 5 0.47). Three out of the
seven patients showed a decrease in viral load during therapy,
but five showed a decrease in viral load prior to therapy as well,
which was not significantly different from an equal chance of a
rise or a fall of viral load (exact B test, two sided, P 5 0.42). In
contrast, for individuals with a high CD41 count, the ratio of
final to initial viral load was significantly less than 1, and it was
significantly less than the change in viral load seen prior to
therapy in the absence of changes in viral fitness (two-sided
approximate t test, unequal variances, P 5 0.036). All eight
individuals with a high CD41 count showed a decrease in viral
load during therapy, compared to four out of eight with a low
CD41 count (exact B test, two sided, P 5 0.027).
Based on the reduction in viral load in individuals with a
CD41 count of 200 or more, the relative fitness of M184V
(during therapy) compared to that of the wild type (in the
absence of therapy) was approximately 30%. This is consistent
with the difference in the enzymatic efficiency of RT as assayed
by using virion-derived RT (45%) (1, 17).
The fitness of M184V relative to that of the wild type may be
much lower than suggested by simply taking the average viral
load reduction for individuals with a CD41 count greater than
200. Figure 4 shows that the variance of the viral load reduc-
tion decreases as CD41 count increases. This is a consequence
of the reduction in viral load swamping the error in measuring
individual viral loads as the reduction in viral load increases. In
the two individuals with the highest CD41 count, the viral load
is reduced to 10% of that prior to therapy, implying that the
relative fitness of M184V is approximately 10% of that of the
wild type. Because target cell compensation may still occur at
high CD41 cell counts, this estimate of relative fitness may be
an overestimate and is much lower than expected based on in
vitro assays of enzyme reactivity.
DISCUSSION
It is widely recognized that the high mutation rate of HIV
will generate a background of resistance-associated mutations
within all patients. These mutants clearly are less fit than the
wild type in the absence of antiretroviral drugs, and the ex-
pected frequency reached by any individual mutation can be
approximated by the balance between the rate of mutation
generating them and the intensity of selection removing them
from the population (9). Coffin (5) applied this deterministic
relationship explicitly to the evolution of drug resistance in
HIV, assuming that the population size of HIV within a patient
was effectively infinite, such that there was no variation be-
FIG. 4. Change in viral load (VL) associated with the outgrowth of M184V
for 16 individuals, together with the best fit obtained from maximum likelihood.
FIG. 5. Changes in the viral load (VL) before therapy (obtained by dividing
initial viral load by viral load obtained 1 to 2 weeks prior to therapy) compared
to the changes in viral load during therapy (obtained by dividing viral load 12
weeks into therapy by initial viral load) for individuals with low (,200) and high
($200) CD41 counts.
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tween individuals due to genetic drift around the frequency at
the mutation-selection balance.
The preexisting frequency of resistance-associated muta-
tions is of immediate significance for the efficacy of antiretro-
viral therapy, and two previous studies have estimated the
frequency of nevirapine and ritonavir resistance mutations,
respectively, prior to therapy (7, 10). These studies suggested
that both the frequency of resistance prior to therapy and the
rate of increase during therapy varied dramatically between
individuals, but the number of patients studied was too few to
establish the levels of variability between patients. We have
used frequency data of two 3TC-resistant mutations, M184I
and M184V, from seven patients on 3TC monotherapy, to
describe the between-host variation in these parameters in
more detail. The simple genetic mechanism of 3TC resistance
makes it unlikely that the rate of outgrowth of M184V will be
confounded by potential interactions between the primary re-
sistance mutation and variation at other sites.
Resistance to 3TC is conferred by two amino acid substitu-
tions at a single site, which each have a substantial fitness
advantage over the wild type in the presence of drug, leading to
a rapid replacement of the wild type in patients on mono-
therapy. Our results confirm that the frequency of M184V
relative to M184I increases approximately deterministically
during therapy and that the fitness advantage is approximately
20%. However, prior to initiation of therapy, the ratio of the
initial frequencies ranged widely from 0.12:1 to 0.33:1 among
the seven patients. Our model accounted for 78% of the vari-
ation in the data. A simpler model which did not allow the
frequency of M184V relative to M184I to vary between indi-
viduals gave a much poorer fit to the data. A more complex
model which allowed the fitness of M184V to also vary be-
tween individuals gave a biologically unrealistic negative cor-
relation between prior frequency and fitness. Analysis of an
explicit mathematical model indicated that genetic drift is
likely to be important before therapy when both mutations are
rare, and it may also play a part during the early stages of
therapy: because the M184V mutant is rarer than M184I, it will
be more subject to sampling effects.
On average, the steady-state viral load when M184V is fixed
in the population is lower than the pretreatment viral load, and
this has been hypothesized to stem from the lower fitness of
M184V relative to the wild type (in the absence of drug).
However, the reduction in viral load is highly variable between
individuals. We have shown that a reduction in viral load is not
seen in individuals with a low CD41 count. One possible ex-
planation for this observation is suggested by a theoretical
study by Bonhoeffer et al. (2). They showed that under simple
models of virus dynamics, changes in viral fitness may be com-
pensated for by changes in target cell availability. Individuals
with high CD41 counts do show a dramatic drop in viral load:
more robust immune responses in these individuals could po-
tentially weaken the negative feedback between viral fitness
and target cell availability. The remaining variation in the
reduction in viral load can be explained simply by the appar-
ently stochastic variation in the viral load over time. Based
upon individuals with a high CD41 count, where the viral
burden is most likely to reflect viral fitness, we estimate that
the fitness of M184V in the presence of drug is approximately
10% of that of wild-type virus in the absence of drug.
The role of chance in HIV evolution is currently a topic of
much debate, which has major implications for the evolution of
drug resistance. Given the large number (107 to 108) (4) of
infected cells in the body, it has been proposed that chance
effects are not important (5). However, it has been proposed
from analysis of variation in env sequences that the effective
population size (Ne) may be substantially lower than this (19).
This could arise if the variance in the number of infected cells
produced per infected cells is high (which can arise due to poor
mixing in the body) or from conflicting selective pressures (8).
The dramatic between-host variations observed in the timing
and pattern of HIV drug resistance mutations during therapy
are also consistent with a role for stochastic evolution (20, 23).
Recently, Rouzine and Coffin (25) have argued that the effec-
tive population size within the host must be greater than 105,
based on a study of variation in HIV-1 protease, and concluded
that stochastic effects will be unimportant for the evolution of
single mutations. In contrast, we have shown that even at
effective population sizes as high as 106, genetic drift is suffi-
cient to generate variation in the frequency of resistant mu-
tants prior to therapy, which arises due to genetic drift having
a larger effect on the relative numbers of rare mutants than on
each mutant individually. Even small differences between in-
dividuals in the relative frequency of rare mutants can result in
dramatic differences in the timing of the outgrowth of the
fittest resistant mutant. We conclude that stochastic effects are
important for single point mutants when these mutants are
competing with each other.
The evolution of resistance to 3TC monotherapy, where
amino acid substitutions at a single site confer 100-fold reduc-
tions in susceptibility to the drug, is at first sight a classical
example of deterministic evolution, and yet we have shown that
even in this case, the ratio of the frequency of two rare mu-
tants, such as the M184V and M184I mutants considered here,
varies significantly between patients as well as within a patient
over time (results not shown), with direct consequences for the
time taken for maximum resistance to be seen. We have also
shown that random fluctuations in measurements of viral load
can give the false impression that viral fitness varies between
individuals and that the impact of a given viral fitness may
differ between individuals. In the current clinical context, 3TC
is used as a component of multidrug regimens, which usually
include zidovudine. Resistance to both drugs involves multiple
substitutions at additional sites, which include site 210 in ad-
dition to changes seen under single-drug therapy at 184 and
215 (15, 22): although not well understood, the fitness differ-
ences between the different combinations are almost certainly
smaller than the fitness differences observed here between
M184V and M184I. In addition, multiple mutants will also
occur at a lower frequency than single mutants. The relevance
of stochastic variation over time and between patients in the
evolution of resistance to combination therapy is therefore
likely to be substantially greater than in the simple system
described here.
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